Bridgebio Pharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5.5% of BridgeBio Pharma, Inc.'s common stock as of June 30, 2026.
NASDAQ
Farallon Capital Management and its affiliates have reported a 5.2% beneficial ownership stake in BridgeBio Pharma, Inc.
NASDAQ
Janus Henderson Group plc has reported beneficial ownership of 13,179,013 shares, representing 6.8% of the outstanding common stock of BridgeBio Pharma, Inc.
NASDAQ
Dr. Neil Kumar filed an amendment to his Schedule 13G, disclosing a 4.6% beneficial ownership stake in BridgeBio Pharma, Inc. as of March 31, 2026.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Bridgebio Pharma Inc. following an internal realignment.
NASDAQ
Janus Henderson Group plc has reported a 5.7% beneficial ownership stake in BridgeBio Pharma, Inc., holding over 11 million common shares.
NASDAQ
T. Rowe Price Associates, Inc. has reported a 1.1% beneficial ownership stake in BridgeBio Oncology Therapeutics Inc., totaling 885,042 shares of common stock.
NASDAQ
The Vanguard Group has reported a beneficial ownership of 8.68% in Bridgebio Pharma Inc., totaling 16,484,985 common shares.
NASDAQ
Dr. Neil Kumar, a key figure, has disclosed a beneficial ownership of 5.41% in BridgeBio Pharma, Inc., totaling 10,466,712 shares as of December 31, 2024.